Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study

被引：0
|
作者：
Xiaoyang Zhai
Wanhu Li
Ji Li
Wenxiao Jia
Wang Jing
Yaru Tian
Shuhui Xu
Yuying Li
Hui Zhu
Jinming Yu
机构：
[1] Shantou University Medical College,Department of Radiation Oncology, Shandong Cancer Hospital and Institute
[2] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Radiology, Shandong Cancer Hospital and Institute
[3] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Oncology
[4] Renmin Hospital of Wuhan University,Department of Radiation Oncology
[5] Shandong Cancer Hospital and Institute Affiliated to Shandong University,undefined
[6] Shandong First Medical University,undefined
[7] Shandong Academy of Medical Sciences,undefined
来源：
Radiation Oncology | / 16卷
关键词：
Osimertinib; Cranial radiotherapy; Brain metastases; Leukoencephalopathy; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A Multi-Center, Open-Label, Randomized, Two-Arm Study, to Evaluate the Efficacy of Osimertinib with Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients with EGFR-Mutated NSCLC and Asymptomatic Brain Metastases
    Blumenfeld, P. A.
    Marwaha, G.
    Shoshan, Y.
    Feldman, J.
    Nechushtan, H.
    Rottenberg, Y.
    Hirsch, N.
    Sheva, K.
    Meirovitz, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E15 - E16
  • [22] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [23] Tesevatinib in NSCLC Patients with EGFR Activating Mutations and Brain Metastases (BM) or Leptomeningeal Metastases (LM)
    Berz, Davic
    Subrananiam, Deepa
    Tonra, James
    Berger, Mark
    Camidge, D. Ross
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S942 - S943
  • [24] FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation
    Zhou, Q.
    Xu, C.
    Chen, H.
    Tu, H.
    Wang, B.
    Yan, H.
    Zhang, X.
    Yang, J.
    Zhong, W.
    Liu, S.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [25] Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study
    Higaki, Hajime
    Nishioka, Kentaro
    Otsuka, Manami
    Nishikawa, Noboru
    Shido, Motoyasu
    Minatogawa, Hideki
    Nishikawa, Yukiko
    Takashina, Rikiya
    Hashimoto, Takayuki
    Katoh, Norio
    Taguchi, Hiroshi
    Kinoshita, Rumiko
    Yasuda, Koichi
    Mori, Takashi
    Uchinami, Yusuke
    Koizumi, Fuki
    Fujita, Yoshihiro
    Takahashi, Shuhei
    Hattori, Takahiro
    Nishiyama, Noriaki
    Aoyama, Hidefumi
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [26] Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study)
    Xing, L.
    Pan, Y.
    Shi, Y.
    Shu, Y.
    Feng, J.
    Li, W.
    Cao, L.
    Wang, L.
    Gu, W.
    Song, Y.
    Yu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
  • [27] Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases
    Dohm, A. E.
    Tang, J.
    Mills, M. N.
    Perez, B. A.
    Robinson, T. J.
    Creelan, B.
    Yu, H. H. M.
    Oliver, D. E.
    Ahmed, K. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E14 - E14
  • [28] Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
    Gulikers, Judith L.
    Veerman, G. D. Marijn
    Jebbink, Merel
    Kruithof, Paul D.
    Steendam, Christi M. J.
    Boosman, Rene J.
    Mathijssen, Ron H. J.
    Tjan-Heijnen, Vivianne C. G.
    Driessen, Johanna H. M.
    Dursun, Safiye
    Smit, Egbert F.
    Dingemans, Anne -Marie C.
    van Geel, Robin M. J. M.
    Croes, Sander
    Hendriks, Lizza E. L.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
  • [29] Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
    Buder, A.
    Hochmair, M. J.
    Setinek, U.
    Filipits, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib plus /- Radiation Therapy in a Real-World Canadian Cohort
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S434 - S434
12345